Bayer Aktiengesellschaft Receivables

Bayer Aktiengesellschaft (BAYN.DE) currently reports a receivables of $17B as of June 2026. That compares with $15B in the prior-year period — up 13.3% year over year. Use the charts on this page to explore Bayer Aktiengesellschaft's receivables history and peer comparisons.

Bayer Aktiengesellschaft's receivables increased from $15B to $17B — a 13.3% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bayer Aktiengesellschaft reported $17B in receivables as of June 2026. That compares with $15B in the prior-year period — up 13.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $17B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bayer Aktiengesellschaft, and consider following BAYN.DE for alerts when major investors trade the stock.

Bayer Aktiengesellschaft is classified in the Healthcare sector. On receivables, it currently shows $17B. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BAYN.DE with unrelated industries.